Home/Filings/4/0001213900-25-090188
4//SEC Filing

Nelabhotla Venkateswarlu 4

Accession 0001213900-25-090188

CIK 0001427570other

Filed

Sep 21, 8:00 PM ET

Accepted

Sep 22, 5:24 PM ET

Size

5.8 KB

Accession

0001213900-25-090188

Insider Transaction Report

Form 4
Period: 2025-08-15
Nelabhotla Venkateswarlu
DirectorPresident and CEO
Transactions
  • Award

    Common Stock

    2025-08-15+77 total
Footnotes (1)
  • [F1]Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 7 shares of the Issuer's common stock in exchange for 35,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

Documents

1 file

Issuer

Vyome Holdings, Inc

CIK 0001427570

Entity typeother

Related Parties

1
  • filerCIK 0002083546

Filing Metadata

Form type
4
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 5:24 PM ET
Size
5.8 KB